Eli Lilly’s anti-obesity drug Mounjaro became India’s top-selling medicine in October, reflecting the growing demand for effective weight-loss treatments. Market data shows a surge in prescriptions driven by rising obesity rates, celebrity endorsements, and social media buzz around quick weight management. Experts say Mounjaro’s success lies in its dual action on blood sugar and appetite control, making it popular among both diabetic and non-diabetic users.
